BWD, did you read that Insmed expects to be approved in Europe by the end of 2014 or is that just hopeful (misreading or misinterpreting)? I believe it the "filing" will be before EOY (2014).
Blue, IF they have something behind the curtain which virtually "assures" those buying the secondary shares a decent gain, then perhaps you are correct. How do we know if in fact there is a $2.5B offer contingent on cash exceeding $120M (making that up) and the extra shares won't matter (except to us)? So, in essence, the $51 PT is about as close to accurate as is Wade's $7 in a sense. If we only "knew" this was coming, would we not buy more now? This is almost the only way this makes any sense OR these "guys" in control are borderline stupid. Guess we have to let this play out now. The PPS is too low for me to sell any.
Tom, the fact that there is no PPS offering amount (could be $11.50 or close to what you posted) the market will drag this down just because it can. This could be close to 20% dilution and it could be construed as a 20% cut from what was already discounted the last week. Kind of ridiculous that management put us here (again and again).
That "genius" was Greg Wade who was sent packing by Wedbush. He made a "call" on ECYT for $65/PT and logged it on Wedbush's "best ideas list". ECYT is now at $6.84 (after over 3 months in low $6's).
Dy2ski - It is not that we did not expect a secondary (if no partner) since we all saw that cash was not sufficient for a PH III trial. But, what morons would wait until their PPS was at its lowest (instead of the $18-$20) to garner needed cash? We are dealing now from a position of weakness (as the market will show us soon) instead of strength just 6 weeks ago. We will be no better off than we were 1 year ago but just more diluted AND what happens if another Analyst comes along and says $7 just because he could?
How does that work? We dilute by 20% and then get bought out for less than (per share) than what we had? Yes, they would get $80M more cash in the coffers so what would that make the buyout price for $2B-$3B??? Pipe Jaffray JUST reiterated its $51 PT last week, doubt Schimmer would change that. MAYbe that is what the PPS for the buyout will be which would make it less than $2B now. Just plain sucks guys!!
Even though the product will be successful. Maybe 47-48M shares after this is done?
Exactly and this borders on stupidity and lack of planning. BUT how does Schimmer stick with his $51 PT and HE is a part of this offering along with JMP. This is why they met individually in May and June. WHY would they wait until now when they had maybe $18/shr in late June/Early July. We will suffer the market's wrath tomorrow and it won't be pretty (even if they state $11 or $11.50/shr).
Amicus Therapeutics Inc. (NASDAQ: FOLD) has been on fire and has recently seen some very large insider buying. Wall Street analysts at JPMorgan and other firms that we cover are very positive on the outcome of the Phase 3 Study 012 data for Amigal. Many are assigning 75% and 50% probabilities of approval success in the EU and the U.S., up from 20% earlier this year. The JPMorgan analysts continue to believe Study 012 has a high probability of success and they are forecasting peak worldwide sales of around $200 million for the migalastat monotherapy treatment for Fabry disease. Their price target for the stock is $7, and the consensus price target for the stock is $6. Amicus closed Friday at $4.14. Trading to the JPMorgan target would be almost a 70% gain.
Blasé, it was me and it was all the questions posted were what the Analysts (Piper Jaffray, UBS, Leerink and JMP) asked last Monday. My point was (now that all those posts were deleted) IF what was announced was so drastic or unexpected or so negative WHY did these Analysts not changed their "performance" rating (Hold or Sell versus BUY) or their PTS in the next 6-9 months?? What do they know or see or expect that the Nefarious jerks here fail to see or accept? Also, I did not have Lewis's answers from the transcript so Reuters wants $100 to buy the whole package.
Levon et al, what has changed since January/February? So much more progress has been made but the PPS is suffering beyond reason. This is from February (buyouts/expiring patents):
In 2014, nearly $50 billion in pharmaceuticals will be going off patent, according to Bloomberg.
Sanofi (NYSE ADR: SNY), Novartis AG (NYSE ADR: NVS), Roche Holding Ltd. (RHHBY), AstraZeneca PLC (NYSE ADR: AZN), and Eli Lilly & Co. (NYSE: LLY) will all be losing more than $6 billion each in annual revenue this year due to expiring patents.
These large-cap pharmaceutical companies, instead of starting from scratch on a new patent, want an easier and more effective way to replace their lost "cash-cow" revenue. They will look to acquire biotech companies - and their phase II or phase III drugs.
The ideal candidates are small-cap biotech firms whose pipelines include late-stage drug candidates or other promising pharmaceuticals.
With that criteria in mind, here are six small-cap biotech firms on the list of takeover targets to watch in 2014...
Biotech Takeover Targets in 2014
Insmed Inc. (Nasdaq: INSM) primarily develops inhalation therapies for the treatment of lung diseases. Insmed's most notable project is ARIKACE, an inhaled antibiotic for patients suffering from cystic fibrosis and non-tuberculous mycobacteria. Currently, ARIKACE is in phase II trials in the United States and phase III trials in Canada and Europe.
INSM stock has gained an impressive 241% in the last year and currently trades at $19.73. Insmed has a market cap of just $772 million, which also makes it an attractive takeover option for large-cap pharmaceutical companies.
Associate Scientist - Inhalation .Bridgewater, NJ
The Associate Scientist will be engaged in the design and development of novel formulations intended for delivery by inhalation, and their physical-chemical characterization.
◾Plan, design and implement experiments to develop novel formulations.
◾Prepare formulations involving nanoparticles, dry powder particles and/or Metered Dose inhaler (MDI).
◾Characterize formulations using appropriate analytical techniques, such as, but not limited to HPLC, optical and fluorescent spectroscopy, particle size assessment, aerosol and powder characterization, microscopy and other.
◾Develop analytical methods.
◾Maintain laboratory equipment.
◾Prepare reports and maintain records, as necessary.
Cortendo AB (OSE:CORT) announces the appointment of Matthew Pauls as President and Chief Executive Officer effective Monday, August 25, 2014.
“It is a pleasure to take over the leadership of Cortendo at such a pivotal time in the development of the company. I'm excited about the opportunity to build a premier global biopharmaceutical company dedicated to serving patients who suffer from serious endocrine diseases with emphasis in orphan indications”
Mr. Pauls brings to Cortendo more than 20 years of experience in the pharmaceutical industry, including senior-level leadership roles in most operational areas, in particular new product launches and commercial operations, clinical development, and technical operations. Mr. Pauls experience includes positions at both leading pharmaceutical companies and at small, publicly traded biopharmaceutical companies like Insmed, Inc., focusing on orphan drug therapies.
Commenting on the appointment, Cortendo’s current CEO and board member Dr. H. Joseph Reiser:
"We are delighted to have an executive of Matt's caliber take over the leadership of Cortendo as we are orienting the company toward product commercialization. Matt’s experience in successfully launching and building several global product portfolios, and proven track record in product development, team building and financing, will further support Cortendo’s strategy to become a leading global biopharmaceutical company.”
Prior to joining Cortendo, Mr. Pauls was Chief Commercial Officer of Insmed, Inc, a publicly traded biopharmaceutical company. In this role, Mr. Pauls built out the global commercial strategy and organization, and led the global technical operations efforts. Mr. Pauls also played a key role in investor interactions and financings. Prior to Insmed, Mr. Pauls worked at Shire Pharmaceuticals, most recently as Senior Vice President, Head of Global Commercial Operations. etc,
Maybe this helps (don't have the shares)?
New grant $323,155 (Insmed Incorporated) 06/02/2014
Equity vested $614,000 (Insmed Incorporated)04/01/2014
Matthew Pauls's Biography (he is 44 years old and now a CEO)
Mr. Pauls joined Insmed as Chief Commercial Officer on April 1, 2013. Mr. Pauls brings more than 20 years of experience in the pharmaceutical industry, including senior-level leadership roles in global marketing, US marketing, general management, sales management, reimbursement, new product launches and commercial operations at leading pharmaceutical companies. From July 2007 to March 2013, Mr. Pauls served in various senior commercial positions with several divisions of Shire Pharmaceuticals, Inc., a U.S. subsidiary of Shire PLC (LSE: SHP), a global biopharmaceutical company. Most recently, he served as Senior Vice President, Head of Global Commercial Operations, Shire Regenerative Medicine, Inc. Prior to that he served as Vice President, Head of Global Commercial Operations, Shire Specialty Pharmaceuticals, Shire Regenerative Medicine; Vice President, Product General Manager of the Behavioral Health Business Unit of Shire Specialty Pharmaceuticals; Vice President, Product General Manager of the ADHD Business Unit of Shire Specialty Pharmaceuticals; and General Manager of the ADHD Business Unit of Shire Specialty Pharmaceuticals. From 2005 to 2007, Mr. Pauls served in the senior management of Bristol-Myers Squibb Company. From 1997 to 2005, Mr. Pauls held various positions at Johnson & Johnson, Inc. Mr. Pauls received his Juris Doctor degree from Michigan State University College of Law and his Master of Business Administration and Bachelor of Science degrees from Central Michigan University.
Source: Insmed Incorporated on 04/17/2014
If he just left "due to personal reasons", I would be concerned. He left for a CEO position. Not many of those around. What other company is in Sweden? Where did Brennan come from? Just never know what is behind these "curtains" anymore. Also, they removed the whole sales staff from their deck presentations in June.
No dilution in the next 18 months:
Cash Position: Cash, cash equivalents and marketable securities as of June 30, 2014 were $59.2 million, compared to $65.8 million as of March 31, 2014. Genocea expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements until at least the end of 2015.
Agree, probably early July as we had a solid PPS between $19-$20 at the time. There has to be more to this "funding" story OR they were gambling on quick approval which we all knew there was another PH III trial imminent. Also, Pauls leaving may not be a negative but because he was Chief commercial Officer he would have had some delay AND he gets a CEO job. Always good to have a solid network across the industry. Where are they building a 3rd manufacturing facility (Japan?)? (or am I misreading the $6-$8m additional expense in 2H 2014)
Balance Sheet Highlights and Cash Guidance
As of June 30, 2014, Insmed had cash and cash equivalents of $82.7 million and working capital of $64.9 million. Excluding depreciation and non-cash stock compensation expense, the Company’s cash operating expenses for the three months ended June 30, 2014 was $19.7 million and includes expenditures of $2.1 million related to the build out of additional and redundant third party manufacturing capacity.
During the second half of 2014, the Company plans to continue to fund further clinical development of ARIKAYCE, increase its investment in third-party manufacturing capacity, support efforts to obtain regulatory approvals and prepare for ARIKAYCE commercialization. As a result, Insmed estimates that its cash operating expenses for the second half of 2014 will be in the range of $42 million to $47 million, which includes additional expenditures of $6 million to $8 million for third-party manufacturing capacity. In addition, in the second half of 2014 the Company expects to invest $2.5 million to $3.5 million in new capital expenditures and pay current liabilities of $2.5 million related to the Company’s new office and laboratory facilities in Bridgewater, N.J. The Company expects current cash balances will be sufficient to fund operations into 2015.
Senior Leadership Team Update
Matthew Pauls, Chief Commercial Officer (CCO), will be leaving Insmed in August 2014 to become the Chief Executive Officer of a biopharmaceutical company based in Sweden and the U.S. Insmed plans to initiate a search to identify a new CCO.
Gina Eagle, MD, was recently promoted to Vice President of Clinical Development. Dr. Eagle is responsible for designing and overseeing the clinical trials and development of the Company's product candidates. Dr. Eagle spent 6 years practicing medicine and has more than 9 years of experience in clinical development in the pharmaceutical industry.